FOLH1 and cancer: In this study, we report on the development and functional characterization of a bispecific monocyte engager capable of simultaneously targeting PSMA-positive cancer cells and the Fc gamma receptor I (FcγRI/CD64) receptor present on the monocyte/macrophage surface.